(Q35720807)

9 August 2017

title

Pyridorin in type 2 diabetic nephropathy (English)

1 reference

Collaborative Study Group

9 August 2017

author

17

object named as

Collaborative Study Group

1 reference

9 August 2017

Edmund J Lewis

1

1 reference

9 August 2017

Tom Greene

2

1 reference

9 August 2017

Samuel Spitalewiz

3

1 reference

9 August 2017

Samuel Blumenthal

4

1 reference

9 August 2017

Tomas Berl

5

1 reference

9 August 2017

Lawrence G Hunsicker

6

1 reference

9 August 2017

Marc A Pohl

7

1 reference

9 August 2017

Richard D Rohde

8

1 reference

9 August 2017

Itamar Raz

9

1 reference

9 August 2017

Yair Yerushalmy

10

1 reference

9 August 2017

Yoram Yagil

11

1 reference

9 August 2017

Tommy Herskovits

12

1 reference

9 August 2017

Robert C Atkins

13

1 reference

9 August 2017

Anne T Reutens

14

1 reference

9 August 2017

David K Packham

15

1 reference

9 August 2017

Julia B Lewis

16

1 reference

9 August 2017

publication date

27 October 2011

1 reference

Journal of the American Society of Nephrology

9 August 2017

published in

1 reference

9 August 2017

volume

23

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

131-136

1 reference

Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Advanced protein glycosylation in diabetes and aging

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Structural-functional relationships in diabetic nephropathy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes --- United States and Puerto Rico, 1996-2007.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269925

Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine

25 September 2018

1 reference

12 December 2020

Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease

1 reference

12 December 2020

Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients

1 reference

12 December 2020

In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways

1 reference

12 December 2020

Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice

1 reference

12 December 2020

Identifiers

DOI

10.1681/ASN.2011030272

1 reference

9 August 2017

1 reference

9 August 2017

1 reference